Novartis AG's Pluvicto has shown statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in pre-taxane setting. The Phase III PSMAfore trial with Pluvicto met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411. Pluvicto also showed improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints. Novartis is investigating a broad portfolio of RLTs in advanced cancers and is investing in production capacity to meet global patient needs.